N/A
Completed N=30
Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
Source: ClinicalTrials.gov NCT01186003 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcomePrimary: Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) — 14; 3 Participants
Summary
The investigators anticipate that the use of Detemir will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin drip is discontinued.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) |
14; 3 | — |
| SECONDARY Reduction in Duration of Insulin Drip Therapy and Reduction in Total and Average Per Hour Insulin Drip Dose |
— | — |
| SECONDARY Reduction in ICU Length of Stay |
— | — |
| SECONDARY Equal or Improved Diabetes Control |
— | — |
| SECONDARY Reduction in Time to Get Back to Control of Glycemia (140-180 mg/dl) if Rebound Hyperglycemia Occurs |
— | — |
Eligibility Criteria
Inclusion Criteria
- Diabetic ketoacidosis (DKA) and hyperosmolar non-ketotic states, hyperglycemia with severe illness, pre-and postoperative states, nothing by mouth (NPO), as well as gastric (tube feeding) and parenteral nutritional requiring insulin drip.
- Patients with type 1 and type 2 diabetes mellitus (DM) will be included.
- Patient with both types of diabetes will be among those treated with insulin drip while being NPO, having severe concomitant illness or receiving enteral and parenteral nutrition
- Patients will be of age 19 to 80.
Exclusion Criteria
- Inability to consent for the study for any reason including cognitive impairment secondary to hyperglycemia, presence of severe medical conditions requiring intubation, severe sepsis, hypothermia, and anticipated length of insulin drop 2 weeks and longer, pregnancy, Levemir allergy, and concurrent sulfonamide treatment
Data sourced from ClinicalTrials.gov (NCT01186003). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.